Jakobsen M, Kolodziejczyk C, Jensen MS et al (2021) Cardiovascular disease in women with breast cancer - a nationwide cohort study. BMC Cancer 21(1):1040
Article PubMed PubMed Central Google Scholar
Akram M, Iqbal M, Daniyal M, Khan AU (2017) Awareness and current knowledge of breast cancer. Biol Res 50(1):33. https://doi.org/10.1186/s40659-017-0140-9
Article CAS PubMed PubMed Central Google Scholar
Miller KD, Nogueira L, Devasia T et al (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 72(5):409–436
Gernaat SAM, Ho PJ, Rijnberg N et al (2017) Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat 164(3):537–555
Article CAS PubMed PubMed Central Google Scholar
Guha A, Fradley MG, Dent SF et al (2022) Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J 43(4):300–312
Abdel-Qadir H, Thavendiranathan P, Austin PC et al (2019) The risk of heart failure and other cardiovascular hospitalizations after early stage breast cancer: a matched cohort study. J Natl Cancer Inst 111(8):854–862
Article PubMed PubMed Central Google Scholar
Yu AF, Singh JC, Wang R et al (2017) Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist 22(6):642–647
Article CAS PubMed PubMed Central Google Scholar
Padegimas A, Clasen S, Ky B (2020) Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med 30(1):22–28
Article CAS PubMed Google Scholar
Essa H, Wright DJ, Dobson R, Lip GYH (2021) Chemotherapy-induced arrhythmia - underrecognized and undertreated. Am J Med 134(10):1224–1231.e1
Barish R, Lynce F, Unger K, Barac A (2019) Management of cardiovascular disease in women with breast cancer. Circulation 139(8):1110–1120
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185–229
Article CAS PubMed Google Scholar
Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 6(11):638–647
Article CAS PubMed Google Scholar
Luengo A, Gui DY, Vander Heiden MG (2017) Targeting metabolism for cancer therapy. Cell Chem Biol 24(9):1161–1180
Article CAS PubMed PubMed Central Google Scholar
Zhu L, Chen L (2019) Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 13(24):40
Ramin C, Schaeffer ML, Zheng Z et al (2021) All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. J Natl Cancer Inst 113(2):137–145
Herrmann J (2019) From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J 40(48):3898–3900
Chen DH, Tyebally S, Malloupas M et al (2021) Cardiovascular disease amongst women treated for breast cancer: traditional cytotoxic chemotherapy, Targeted Therapy, and Radiation Therapy. Curr Cardiol Rep 23(3):16
Mehta LS, Watson KE, Barac A et al (2018) American heart association cardiovascular disease in women and special populations committee of the council on clinical cardiology; council on cardiovascular and stroke nursing; and council on quality of care and outcomes research. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the american heart association. Circulation 137(8):e30-e66
Blaes AH, Konety SH (2021) Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship. J Natl Cancer Inst 113(2):105–106
Porta-Sánchez A, Gilbert C, Spears D et al (2017) Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 6(12):e007724
Article PubMed PubMed Central Google Scholar
Okwuosa TM, Anzevino S, Rao R (2017) Cardiovascular disease in cancer survivors. Postgrad Med J 93(1096):82–90
Greenlee H, Iribarren C, Rana JS et al (2022) Risk of cardiovascular disease in women with and without breast cancer: the pathways heart study. J Clin Oncol 40(15):1647–1658
Article PubMed PubMed Central Google Scholar
Lee K, Tripathy D, Demark-Wahnefried W et al (2019) Effect of aerobic and resistance exercise intervention on cardiovascular disease risk in women with early-stage breast cancer: a randomized clinical trial. JAMA Oncol 5(5):710–714
Article PubMed PubMed Central Google Scholar
Sturgeon KM, Deng L, Bluethmann SM et al (2019) A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 40(48):3889–3897
Article PubMed PubMed Central Google Scholar
Zagar TM, Cardinale DM, Marks LB (2016) Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol 13(3):172–184
Article CAS PubMed Google Scholar
Meattini I, Poortmans PM, Aznar MC et al (2021) Association of breast cancer irradiation with cardiac toxic effects: a narrative review. JAMA Oncol 7(6):924–932
Kirkham AA, Beaudry RI, Paterson DI, Mackey JR, Haykowsky MJ (2019) Curing breast cancer and killing the heart: a novel model to explain elevated cardiovascular disease and mortality risk among women with early stage breast cancer. Prog Cardiovasc Dis 62(2):116–126
Malik M (2016) Drug-induced QT/QTc interval shortening: lessons from drug-induced QT/QTc prolongation. Drug Saf 39(7):647–659
Article CAS PubMed Google Scholar
Farmakis D, Filippatos G (2021) Arrhythmias in cancer: rhythm is gonna get you! Eur J Heart Fail 23(1):154–156
Galetta F, Franzoni F, Cervetti G et al (2005) Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 59(10):541–544
Article CAS PubMed Google Scholar
Hulst MB, Grocholski T, Neefjes JJC, van Wezel GP, Metsä-Ketelä M (2022) Anthracyclines: biosynthesis, engineering and clinical applications. Nat Prod Rep 39(4):814–841
Article CAS PubMed Google Scholar
Benjanuwattra J, Siri-Angkul N, Chattipakorn SC, Chattipakorn N (2020) doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies. Pharmacol Res 151:104542
Article CAS PubMed Google Scholar
Prathumsap N, Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N (2020) Effects of doxorubicin on the heart: from molecular mechanisms to intervention strategies. Eur J Pharmacol 5(866):172818
Osataphan N, Phrommintikul A, Leemasawat K et al (2023) Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial. Sci Rep 13(1):12759
Comments (0)